In light of their closely related mechanisms of action, and preliminary clinical evidence suggesting that they possess similar efficacies, it has been anecdotally suggested that vigabatrin and tiagabine may prove to be therapeutically indistinguishable. As a result, we have conducted a preclinical comparison of their anticonvulsant profile and mechanism of action. Pentylenetetrazol and maximal electroshock seizures were employed to determine the experimental anticonvulsant profile. Mechanisms of action were investigated using assays of γ -aminobutyric acid (GABA), GABA-transaminase and glutamic acid decarboxylase in mouse brain and GABA uptake and GABA-transaminase in rat astrocyte cultures. Vigabatrin was without effect on either pentylenetetrazol-or maximal electroshock-induced seizures, whereas tiagabine increased the latency to pentylenetetrazol seizures and reduced the incidence of maximal electroshock seizures. In mouse brain assays, tiagabine was without effect, while vigabatrin increased GABA concentrations and reduced GABA-transaminase and glutamic acid decarboxylase activities. In cortical astrocyte cultures, vigabatrin reduced the activities of both GABA uptake and GABA-transaminase, whereas tiagabine blocked GABA uptake alone. These results suggest that vigabatrin and tiagabine have differing efficacy in experimental seizure models and distinct neurochemical effects. It is possible, then, that these drugs will have different spectra of activity and toxicity profiles in human epilepsy.
INTRODUCTION
In the 10-15 year period leading up to 1989, there was a hiatus in the introduction of novel therapies for epilepsy. Since then, however, eight new antiepileptic drugs have reached the global market-place 1 . These new generation pharmaceuticals represent the first fruits of an intensive rational drug design and development programme aimed at addressing the significant clinical problem of refractory epilepsy 2, 3 . Much of these efforts have been targeted towards the investigation of glutamate and γ -aminobutyric acid (GABA) as the principal excitatory and inhibitory neurotransmitters, respectively, in the mammalian brain 4, 5 .
Potentiation of GABA is regarded as one of the most attractive mechanisms of action for novel antiepileptic agents and can be achieved by increased synthesis or release, receptor-dependent modulation, or reduced inactivation of this important neurotransmitter 6 . GABA * E-mail: g.j.sills@clinmed.gla.ac.uk inactivation is a two-step process, initially involving a specific sodium-and energy-dependent cellular uptake 7 and culminating in a mitochondrial metabolism catalysed by the enzyme GABA-transaminase 8 . Vigabatrin and tiagabine are two of the new generation of antiepileptic drugs 9 , both of which are believed to exert their pharmacological effects via single and specific actions on GABA inactivation 10, 11 .
Vigabatrin is an ethyl analogue of GABA and has been proposed to work by an irreversible inhibition of GABA-transaminase [12] [13] [14] . In contrast, tiagabine is a nipecotic acid derivative which is believed to act by blockade of GABA uptake into neurones and glial cells 15, 16 . Inhibition of GABA-transaminase results in an increase in whole brain GABA concentration 17, 18 whereas blockade of GABA uptake temporarily sustains levels of endogenously released GABA in the synapse 16 . Clinically, both drugs appear to have particular efficacy against partial seizures with or without secondary generalization 19, 20 .
With closely related effects on GABA inactivation as their mechanisms of action and similar clinical efficacies, it can be suggested that vigabatrin and tiagabine may prove to be therapeutically indistinguishable. The aims of the following studies, therefore, were to compare and contrast the experimental anticonvulsant profiles and mechanisms of action of these two new GABAergic antiepileptic agents using the traditional pentylenetetrazol and maximal electroshock seizure tests and a battery of GABA-related neurochemical assays in mouse cortex and primary rat astrocyte cultures.
MATERIALS AND METHODS
Vigabatrin (D,L-4-aminohex-5-enoic acid) and tiagabine ((R-)-(-)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidine-carboxylic acid, hydrochloride) were kind gifts from Marion Merrell Dow (Winnersh, UK) and Novo Nordisk A/S (Bagsvaerd, Denmark) respectively. Radiolabelled GABA (γ -[ 14 C(U)]-aminobutyric acid) was obtained from NEN Research Products (Stevenage, UK). Cell culture grade Dulbecco's modified Eagle medium, horse serum, L-glutamine, penicillin and streptomycin were obtained from Gibco BRL (Paisley, UK). All other chemicals (reagent grade) were obtained from the Sigma Chemical Company (Poole, UK) and solvents were purchased from Rathburn Chemicals (Walkerburn, UK).
Whole animal studies were performed in groups of adult, male ICR mice (25-30 g; Harlan Olac, Bicester, UK), housed in a controlled temperature/humidity environment with a 12 hour day/night cycle and allowed access to food and water ad libitum. Cell culture studies were performed in primary cultures of rat cortical astrocytes isolated and maintained by the methods described by Leach and colleagues 21 . All experimental work was governed by the Animals (Scientific Procedures) Act, 1986 (UK).
Pentylenetetrazol-induced seizures
Pentylenetetrazol seizures were induced in accordance with the method described by Löscher and Schmidt 22 . Pentylenetetrazol was administered subcutaneously in the back of the neck in a dose of 85 mg/kg in 0.9% saline. The latency to the first observed generalized seizure with loss of the righting reflex was recorded.
Electroshock-induced seizures
Electroshock seizures were induced in accordance with the methods described by Löscher and Schmidt 22 . Constant current electroshock stimuli were delivered via auricular electrodes from a Ugo Basile 7800 ECT unit (Comerio, Italy). Electrodes were moistened with 0.9% saline to improve conductance. Maximal electroshock stimuli consisted of 0.2 seconds of rectangular positive pulses (50 mA at 60 Hz, pulse width = 0.4 ms) to induce tonic hind-limb extension in control animals. The percentage of animals exhibiting tonic hind-limb extension in each treatment group was recorded.
Neurochemical assays
Cortical GABA concentrations, protein concentrations and the activities of GABA-transaminase and glutamic acid decarboxylase were determined as previously described 23 .
GABA uptake and GABA-transaminase activity in astrocyte cultures GABA uptake studies were performed by the methods described by Leach and colleagues 21 . The techniques used in the analysis of GABA-transaminase in astrocyte cultures were a modification of those employed for the analysis of GABA uptake 21 and those described for the whole brain GABA-transaminase assay by Sills and colleagues 23 . Briefly, cultures were prepared and exposed to the appropriate drug concentrations as described for the GABA uptake studies 21 , with the exception of a 3 ml volume being employed for the final one hour drug exposure period. At the end of the drug exposure period, the cultures were washed immediately with five volumes (2 ml) of balanced salt solution (BSS) and the cells removed from the plates in 1 ml ice-cold ethylene diamine tetra-acetic acid buffer (see Ref. 23 for composition). Thereafter the enzyme assay was performed as previously described 23 although protein concentrations of individual cell culture samples were adjusted to 0.2 mg/ml prior to assay as opposed to 1 mg/ml for whole brain samples.
Experimental protocol

Effects of vigabatrin and tiagabine on pentylenetetrazol-induced seizures
Sixty adult male ICR mice (25-30 g) were randomized into five groups (n = 12/group) and vigabatrin was administered intraperitoneally in doses of 25, 50, 100 and 200 mg/kg. The fifth group (control) received vehicle (0.9% saline) alone. Another 60 adult male ICR mice were also randomized into five groups (n = 12/group) and tiagabine was administered intraperitoneally in doses of 0.5, 1, 2 and 5 mg/kg. Again, the fifth group (control) received vehicle (0.9% saline) alone. At 6 hours (tiagabine) and 24 hours (vigabatrin) post-administration, six animals from each group were subjected to pentylenetetrazolinduced seizures as described above. The remaining six animals in each group continued to receive the appropriate control/drug treatment once daily for eight days. At 6 hours (tiagabine) and 24 hours (vigabatrin) after drug administration on the eighth day, the remaining animals were subjected to pentylenetetrazolinduced seizures as described above.
Effects of vigabatrin and tiagabine on maximal electroshock-induced seizures
One hundred adult male ICR mice (25-30 g) were randomized into five groups (n = 20/group) and vigabatrin was administered intraperitoneally in doses of 25, 50, 100 and 200 mg/kg. The fifth group (control) received vehicle (0.9% saline) alone. Another 100 adult male ICR mice were also randomized into five groups (n = 20/group) and tiagabine was administered intraperitoneally in doses of 0.5, 1, 2 and 5 mg/kg. Again, the fifth group (control) received vehicle (0.9% saline) alone. At 6 hours (tiagabine) and 24 hours (vigabatrin) post-administration, 10 animals from each group were subjected to maximal electroshock-induced seizures as described above. The remaining 10 animals in each group continued to receive the appropriate control/drug treatment once daily for eight days. At 6 hours (tiagabine) and 24 hours (vigabatrin) after drug administration on the eighth day, the remaining animals were subjected to maximal electroshock-induced seizures as described above.
Effects of vigabatrin and tiagabine on GABA-related neurochemistry in mouse cortex
Adult male ICR mice were randomized into seven groups (n = 18/group) and administered vigabatrin (10, 50 and 250 mg/kg) or tiagabine (0.4, 2 and 10 mg/kg) intraperitoneally. The seventh group (control) received vehicle (0.9% saline) alone. Treatment was continued once daily for eight days. At 6 hours after the final dose, the animals were sacrificed and their brains removed. The cerebral cortices were dissected free and the samples were stored at −70 • C until required for assay. Six cortices from each group were employed in the investigation of GABA concentration, GABA-transaminase activity and glutamic acid decarboxylase activity.
Effects of vigabatrin and tiagabine on GABA-related neurochemistry in rat astrocyte cultures
Fully matured rat cortical astrocyte cultures were randomized into seven groups (n = 20/group) and exposed to 10, 50, 100, 250, 500 and 1000 µM vigabatrin. The seventh group (control) was exposed to vehicle (BSS) alone. Following a one-hour incubation period, 10 cultures from each group were analysed for GABA uptake activity and the remaining 10 cultures were analysed for GABA-transaminase activity. This experiment was repeated using a further batch of rat astrocyte cultures exposed to 0, 10, 50, 100, 250, 500 and 1000 nM tiagabine for a period of one hour.
Statistical analysis
Statistical analysis was performed using MINITAB for Windows statistical package (Version 10.1) on a Viglen 4DX266 microcomputer. Pentylenetetrazol seizure latencies were expressed as absolute values and compared with control by one-way analysis of variance with Dunnett correction for multiple comparisons. Maximal electroshock seizure data were also expressed as absolute values and compared with control using Fisher's exact test, with a Bonferroni correction for multiple comparisons. GABA concentrations and the activities of GABA-transaminase, glutamic acid decarboxylase and GABA uptake were calculated as the percentage of mean control values. Group results were then expressed as mean percentages ± the standard error of the mean (SEM) and compared with control by one-way analysis of variance with a Dunnett correction for multiple comparisons.
RESULTS
Effects of vigabatrin and tiagabine on pentylenetetrazol-induced seizures
Single dose and repeated treatments with vigabatrin (25-200 mg/kg) were without effect on the latency to the first generalized seizure induced by 85 mg/kg pentylenetetrazol at 24 hours post-administration (Fig. 1a) . In contrast, acute (2 and 5 mg/kg) and chronic (1 mg/kg) treatment with tiagabine significantly increased the time to the first generalized seizure induced by pentylenetetrazol at 6 hours postadministration (Fig. 1b) . 
Effects of vigabatrin and tiagabine on maximal electroshock-induced seizures
Single-dose vigabatrin treatment (25-200 mg/kg) was without effect on the incidence of tonic seizures induced by maximal electroshock at 24 hours postadministration (Fig. 2a) . Repeated treatment with 50 mg/kg vigabatrin significantly reduced the incidence of tonic seizures induced by maximal electroshock at 24 hours after the final dose (Fig. 2a) , although all other doses were without effect. Again, in contrast, acute and chronic treatment with tiagabine (2 and 5 mg/kg) significantly reduced the incidence of tonic seizures induced by maximal electroshock at 6 hours post-administration (Fig. 2b) .
Effects of vigabatrin and tiagabine on GABA-related neurochemistry in mouse cortex
Repeated treatment with vigabatrin (50 and 250 mg/kg) significantly increased cortical GABA concentration and reduced the activities of GABAtransaminase and glutamic acid decarboxylase at 6 hours after the final dose (Fig. 3a) . Repeated treatments with tiagabine (0.4-10 mg/kg) were essentially without effect on any of the parameters investigated, although 2 mg/kg tiagabine significantly increased the activity of GABA-transaminase at 6 hours post-administration (Fig. 3b) . Mean control values (±SEM) for GABA concentration and the activities of GABA-transaminase and glutamic acid decarboxylase were 265.5(±16.6) µg/g, 861.4(±65.8) pmol/mg protein/min and 2.26(±0.19) nmol/mg protein/min, respectively.
Effects of vigabatrin and tiagabine on GABA-related neurochemistry in rat astrocyte cultures
A one-hour exposure to vigabatrin (10-1000 µM) reduced the activity of GABA-transaminase in primary cultures of rat cortical astrocytes in a dose-dependent manner and also significantly reduced GABA uptake into these cells (Fig. 4a) . A one-hour exposure to tiagabine (10-1000 nM) was without effect on GABA-transaminase activity but significantly reduced GABA uptake (Fig. 4b) . Mean control values (±SEM) for GABA-transaminase activity and GABA uptake were 490.4(±35.8) pmol/mg protein/min and 383.9(±35.9) pmol/mg protein/min, respectively.
DISCUSSION
Vigabatrin and tiagabine are new antiepileptic agents with closely related pharmacological actions on GABA inactivation and similar clinical efficacies. The recent preliminary observation 24 that tiagabine monotherapy may have detrimental effects on visual field perimetry in epileptic patients, in a manner similar to that reported for vigabatrin [25] [26] [27] [28] , has fuelled speculation that these drugs may prove to be clinically indistinguishable. In light of this observation, and other such anecdotal reports, the aims of these studies were to compare and contrast vigabatrin and tiagabine in terms of their experimental anticonvulsant profiles and mechanisms of action using the traditional pentylenetetrazol and maximal electroshock tests in mice and a range of GABA-related neurochemical as- says in mouse cortex and primary rat astrocyte cultures.
There is a reasonable body of evidence regarding the effects of vigabatrin and tiagabine on experimental seizures induced by the systemic administration of chemoconvulsant compounds. Both drugs are active against seizures induced by the β-carboline compound methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate [29] [30] [31] whereas it would appear that vigabatrin alone has activity in bicuculline and picrotoxin models [32] [33] [34] . In the above studies, vigabatrin was without effect on pentylenetetrazol-induced seizures, following both single and repeated administration. In contrast, specific doses of tiagabine significantly increased the seizure latency. Although the efficacy of tiagabine in the pentylenetetrazol test is well established 30, 31 , there is a degree of conflict regarding the action of vigabatrin in this model. There is some evidence to suggest that the drug is active against pentylenetetrazol-induced seizures 33, 35, 36 , but there are a similar number of reports to the contrary 31, 34, 37 . On close inspection, it would appear that species and strain differences play a part in this experimental discrepancy, that drug incubation times also influence the results and that an anticonvulsant effect is generally only observed when the dose of vigabatrin is high and that of pentylenetetrazol is moderate to low. Thus, it would appear that tiagabine is effective in the traditional pentylenetetrazol test, while the activity of vigabatrin remains open to debate. In terms of anticonvulsant profiles against chemoconvulsant-induced seizures, the two drugs are clearly different. Of the experimental seizure models which require electrical induction, the kindling and maximal electroshock models are most widely employed and reported. In amygdaloid kindling, both vigabatrin [38] [39] [40] and tiagabine 41 have demonstrated efficacy although it has been suggested that vigabatrin is only effective against generalized seizures in this model, while tiagabine has activity against the focal seizure component also 31 . In the maximal electroshock studies described herein, vigabatrin was essentially without effect, despite an unexplained action following repeated administration of 50 mg/kg of the drug. In contrast, single and repeated administration with higher doses of tiagabine elicited a significant anticonvulsant response. These effects, or indeed lack of them, are again not entirely consistent with previously published data. There is some evidence to suggest that vigabatrin is active against maximal electroshock-induced seizures 42, 43 but generally only following direct micro-injection of the drug into discrete brain regions. It is more widely reported that systemically administered vigabatrin is inactive in this model 22, 33, 34, 44 . Tiagabine has also been reported to be essentially devoid of activity in the maximal electroshock test, although it does appear to have some degree of efficacy at very high dose after a 30-minute pre-treatment period 30, 31 . It is possible, although unlikely with such a short-acting compound 45 , that the anticonvulsant effect of tiagabine in this model is only manifested after a long incubation period, such as the six-hour interval used in this study. Thus, it is unclear whether tiagabine has any activity in the traditional maximal electroshock test, whereas vigabatrin is almost certainly without effect. Although the distinction between the drugs is not as clear cut as with the chemoconvulsant-induced seizures, proposed differences in their efficacy against kindled seizures and potential differences in the maximal electroshock test would suggest that vigabatrin and tiagabine have differing actions in experimental seizure models which rely on electrical induction.
It is well recognized that the mechanisms of action of vigabatrin and tiagabine are similar, in that they have both been reported to exert their pharmacological effects by an inhibition of GABA inactivation 31 . Although mitochondrial GABA metabolism and cellular GABA uptake are clearly separate biochemical phenomena, they are inextricably linked in a physiological sense. It is likely that the temptation to view these two processes collectively has fuelled the speculation of vigabatrin and tiagabine being clinically indistinguishable. The above ex vivo studies have, however, emphasized the clear pharmacological differences between the drugs. Tiagabine was essentially without effect on any of the parameters investigated, although a small, unexplained increase in GABA-transaminase activity was observed following repeated administration of a moderate dose of the drug. In contrast, vigabatrin significantly reduced the activity of GABA-transaminase and, as a result, effected a large increase in cortical GABA concentrations. The drug also reduced the activity of glutamic acid decarboxylase. These actions of vigabatrin have been observed previously [46] [47] [48] and were explained by an effect of the drug on its target enzyme GABA-transaminase, leading to an increase in GABA levels and a resultant decrease in glutamic acid decarboxylase activity by a negative feedback mechanism. Other authors have, however, proposed that vigabatrin has a direct inhibitory effect on glutamic acid decarboxylase following repeated administration 17 . With the methods employed here, it was not possible to ascertain which of these explanations was responsible for the observed inhibition of glutamic acid decarboxylase. These studies have, however, served to highlight the important pharmacological distinction between vigabatrin and tiagabine.
The final investigations also considered the mechanisms of action of vigabatrin and tiagabine, comparing their effects on the uptake and metabolism of GABA in primary cultures of rat cortical astrocytes. A onehour exposure to vigabatrin significantly reduced the uptake of GABA into these cells and effected a dosedependent inhibition of its mitochondrial metabolism by GABA-transaminase. By comparison, tiagabine reduced GABA uptake alone. The inhibitory effects of vigabatrin on GABA-transaminase, and tiagabine on GABA uptake, confirm previous reports on their respective mechanisms of action 12, 13, 15, 16 . In contrast, the effect of vigabatrin on GABA uptake is not widely recognized. Although these findings support the preliminary observations of Leach and co-workers 21 , they contradict those of Schousboe and colleagues 49 . It is possible that the use of mixed glial cell cultures, as opposed to a single cell type culture, may be the confounding factor, with the glial cell composition 50 likely to vary widely between laboratories. Whatever the basis of the discrepancy, if this striking effect of vigabatrin is substantiated in further studies, then an inhibition of GABA uptake would represent an important secondary mechanism of action of the drug and one which could help to explain a variety of anomalies associated with its use in the laboratory 21 and the observation of rebound seizures upon its clinical withdrawal 51 .
In conclusion, the results of these investigations suggest that, in spite of anecdotal reports regarding similarities between vigabatrin and tiagabine, there are clear differences between the drugs in terms of their activities in experimental seizure models. In addition, neurochemical investigations have confirmed the widely reported, and clearly distinct, principal mechanisms of action of the two drugs, but have also uncovered a potentially important, secondary mechanism of vigabatrin action which it may share with tiagabine. There is, therefore, ample evidence, both herein and in the literature, to suggest that the two compounds are sufficiently different, particularly in terms of their activities in experimental seizure models and in their principal mechanisms of action, to assume that they will have different spectra of activity and toxicity in human epilepsy.
